Research Summary
Stephen Hursting, PhD, MPH, is an international leader in the area of nutrition, obesity, metabolism and cancer. His lab focuses on the molecular and metabolic mechanisms underlying obesity-cancer associations, and the impact of obesity- energy balance modulation (eg, calorie restriction and exercise) or pharmacologic agents on cancer development, progression, and responses to chemotherapy. Primarily using genetically engineered mouse models of breast cancer (recently in parallel with several clinical trials), colon cancer and pancreatic cancer, Hursting has identified the IGF1/Akt/mTOR and NF-kB signaling pathways as key targets for breaking the obesity-cancer link. His publications establish causal links between obesity, cancer and several systemic factors (including IGF-1, insulin, leptin and IL-6) and components of their downstream signaling pathways (including mTOR and NF-kb).
